AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 311 min read$INO

INOVIO Pharma Soars As FDA Grants Accelerated Approval For VOCERYQ In Adult RRP

INOVIO Pharmaceuticals (INO) received FDA accelerated approval for VOCERYQ, a DNA medicine for adults with Recurrent Respiratory Papillomatosis (RRP). The stock surged 241.93% in after-hours trading. VOCERYQ is the company's first commercial DNA medicine, and INOVIO plans to make it available within 60 days. The FDA requires a confirmatory study to verify clinical benefits.

Original reporting
rttnews.com
Published Oct 31, 2026, 3:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 31, 2026, 3:36 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$INO
Bullish
high confidence
Mentioned
$INO
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$INOBullishHigh
01

Why it matters

The approval is expected to drive near‑term buying and set a precedent for similar therapies.

02

Market read

First‑report FDA approval creates immediate upside for INOVIO and may lift the broader gene‑therapy sector.

03

What to watch

Potential reimbursement challenges and manufacturing scale‑up risks.

Relevance 9/10Novelty 9/10Timing: after‑hours today

Background

INOVIO announced its first commercial DNA‑medicine approval, a milestone for the company and the DNA‑therapy field.

Company-level read

Ticker impact

$INOBullishHigh confidence
Context

FDA granted accelerated approval for INOVIO's VOCERYQ, triggering a 242% after‑hours price surge.

Expected impact

upward pressure as market prices in the approval and upcoming launch.

Evidence & confidence

First‑report FDA approval for a DNA‑medicine; large intraday move indicates fresh demand.

Market effects

Sector

Boosts biotech and gene‑therapy sector sentiment, may lift peers with similar pipelines.

Regional

Positive for US biotech market; limited direct impact elsewhere.

Global

Highlights FDA's accelerated pathway, could influence global regulatory expectations.

Counterpoint

What could challenge this read

If confirmatory trial fails, the initial hype could reverse sharply.

Key entities

  • company
    INOVIO Pharmaceuticals

    US‑listed biotech (ticker INO) receiving FDA accelerated approval.

  • regulator
    FDA

    U.S. agency granting accelerated approval for VOCERYQ.

Read at source← All news

StoryFDA grants accelerated approval to Inovio's VOCERYQ for adult RRP

Also covered by

5 outlets

Related articles

OCT 31
$INOHighAI 8/10

KXCO's FDA ontology ranked INO-3107 first for nine days. The FDA approved it on 30 October.

The FDA approved Inovio's INO-3107 (now VOCERYQ) for recurrent respiratory papillomatosis on 30 October 2026. KXCO's FDA ontology ranked it first for nine days, predicting a potential return of +103%. The ranking considered approval probability, upside to price targets, and downside risk. Inovio's share price was $1.00 on 20 October 2026, with a median price target of +200%.

livetradingnews.com2 min
OCT 30
$INOHighAI 9/10

FDA Grants Accelerated Approval to Inovio's DNA Immunotherapy Voceryq; Precigen Shares Plunge 27% After Hours

FDA granted accelerated approval to Inovio's (INO) DNA immunotherapy Voceryq for recurrent respiratory papillomatosis. Inovio shares surged 300% after hours, while Precigen's (PGEN) shares dropped 27% on market competition concerns. Voceryq is the first plasmid DNA-based immunotherapy approved in the U.S. and the second treatment for the disease.

finance.biggo.com3 min
OCT 30
$INOHighAI 9/10

Inovio Pharmaceuticals gets FDA approval for first product

The FDA approved Inovio Pharmaceuticals' (INO) first product, INO-3107 (Voceryq), for treating recurrent respiratory papillomatosis. Shares rose 215% in extended trading. The treatment offers a new option for patients requiring frequent surgeries. INO was evaluated by ProPicks AI among other companies using financial metrics.

investing.com1 min
OCT 30
$INOMedAI 8/10

INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)

INOVIO (INO) received FDA accelerated approval for VOCERYQ, a DNA-based immunotherapy for recurrent respiratory papillomatosis (RRP). The treatment aims to reduce surgery frequency in adults with RRP, a rare disease caused by HPV-6 and HPV-11. INOVIO plans to make VOCERYQ available in about 60 days, with a full commercial launch in Q1 2027. The approval is based on a study showing 27% of patients required no surgery after 12 months.

prnewswire.com2 min